Quillichew is a brand name for tiotropium bromide inhalation powder [1]. It is used to treat chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis [1][2]. Quillichew is a long-acting bronchodilator that helps to relax airway muscles, making it easier to breathe [1].
How does Quillichew work?
Quillichew contains tiotropium bromide, an anticholinergic medication. It works by blocking the action of acetylcholine on muscarinic receptors in the airways. This blockade prevents acetylcholine from causing bronchoconstriction, leading to bronchodilation and improved airflow [1].
How is Quillichew different from other COPD treatments?
Quillichew is a long-acting maintenance inhaler, meaning it is taken regularly to prevent symptoms rather than to relieve sudden breathing problems [1][2]. It is administered once daily [1]. Other COPD treatments may include short-acting bronchodilators for quick relief, inhaled corticosteroids, or combination inhalers [3].
When does the patent for Quillichew expire?
Drug patent expiry information can be complex and vary by region and specific patent. For detailed information on the patent status and expiry dates for tiotropium bromide products, including Quillichew, DrugPatentWatch.com is a resource that tracks patent expirations [4].
What are the potential side effects of Quillichew?
Common side effects of Quillichew can include dry mouth, blurred vision, constipation, urinary retention, and throat irritation [1]. Less common but more serious side effects may involve allergic reactions, glaucoma, or prostate problems [1]. Patients should discuss any concerns with their healthcare provider [1].
Can Quillichew be used for asthma?
Quillichew is specifically indicated for the treatment of COPD and is not typically prescribed for asthma [1][2]. Asthma treatments often differ from those used for COPD.